Skip to main content
Top
Published in: Breast Cancer 1/2023

Open Access 30-09-2022 | Breast Cancer | Original Article

A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

Authors: Shozo Ohsumi, Reiki Nishimura, Norikazu Masuda, Sadako Akashi-Tanaka, Kimito Suemasu, Hideko Yamauchi, Eriko Tokunaga, Tadashi Ikeda, Tsunehiro Nishi, Hiroto Hayashi, Yuichi Iino, Yuichi Takatsuka, Yasuo Ohashi, Hideo Inaji

Published in: Breast Cancer | Issue 1/2023

Login to get access

Abstract

Background

Breast-conserving surgery with radiotherapy is one of standard treatments for early breast cancer. However, it is regarded as an option to treat elderly patients with small hormone receptor-positive breast cancer with breast-conserving surgery and hormone therapy without radiotherapy. We conducted two sequential prospective studies to examine the feasibility of breast-conserving surgery without radiotherapy since 2002 and present the results.

Patients and methods

Primary female breast cancer patients who fulfilled the strict eligibility criteria were prospectively enrolled in two sequential studies named WORTH 1 and 2. The surgical materials were sliced in 5-mm intervals and all slices were examined microscopically. Postoperative radiotherapy was not allowed, but tamoxifen or anastrozole was administered for 5 years. Ipsilateral breast tumor recurrence (IBTR)-free survival was the primary outcome.

Results

The data of the two studies were combined (N = 321). The median follow-up period for IBTR was 94 months (4–192 months). Only three patients were treated with adjuvant chemotherapy. The 5- and 10-year IBTR-free rates were 97.0% and 90.5%, respectively. The age at operation and PR status affected IBTR rates independently. When we calculated IBTR-free rates of patients who were 65 years of age or older at the time of surgery and had PR-positive tumors, the 5- and 10-year IBTR rates were both 98.4%.

Conclusions

 Our “5-mm-thick slice and 5-mm free-margin” method may be effective to select patients who can be treated by breast-conserving surgery and hormone therapy without radiotherapy.
Literature
1.
go back to reference Veronesi U, Saccozzi R, Vecchio MD, Banfi A, Clemente C, De Lena M, et al. Comparison of radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancer of the breast. N Engl J Med. 1981;305:6–11.CrossRef Veronesi U, Saccozzi R, Vecchio MD, Banfi A, Clemente C, De Lena M, et al. Comparison of radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancer of the breast. N Engl J Med. 1981;305:6–11.CrossRef
2.
go back to reference Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665–73.CrossRef Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665–73.CrossRef
3.
go back to reference Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 1989;14:177–84.CrossRef Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 1989;14:177–84.CrossRef
4.
go back to reference Lichter AS, Lippman ME, Danforth DN, d’Angelo T, Steinberg SM, deMoss E, et al. Mastectomy versus breast conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10:976–83.CrossRef Lichter AS, Lippman ME, Danforth DN, d’Angelo T, Steinberg SM, deMoss E, et al. Mastectomy versus breast conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10:976–83.CrossRef
5.
go back to reference van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer. EORTC 10801 trial. J Natl Cancer Inst Monogr 1992; 11: 15–8. van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer. EORTC 10801 trial. J Natl Cancer Inst Monogr 1992; 11: 15–8.
6.
go back to reference Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr. 1992;11:19–25. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr. 1992;11:19–25.
7.
go back to reference Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–61.CrossRef Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–61.CrossRef
8.
go back to reference Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995; 333:1444–55. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995; 333:1444–55.
9.
go back to reference Veronesi U, Luini A, Vecchio ID, Greco M, Galimberti V, Merson M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1994;328:1587–91.CrossRef Veronesi U, Luini A, Vecchio ID, Greco M, Galimberti V, Merson M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1994;328:1587–91.CrossRef
10.
go back to reference Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node negative breast cancer: An update. J Natl Cancer Inst. 1996;88:1659–64.CrossRef Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node negative breast cancer: An update. J Natl Cancer Inst. 1996;88:1659–64.CrossRef
11.
go back to reference Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, et al. Randomized controlled trial of conservation therapy: 6-year analysis of Scottish trial. Scottish Cancer Trials Breast Group Lancet. 1996;348:708–13. Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, et al. Randomized controlled trial of conservation therapy: 6-year analysis of Scottish trial. Scottish Cancer Trials Breast Group Lancet. 1996;348:708–13.
12.
go back to reference Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378:1707–16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378:1707–16.
13.
go back to reference Takigawa N, Segawa Y, Saeki T, Kataoka M, Ida M, Kishino D, et al. Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys. 2000;48:751–5.CrossRef Takigawa N, Segawa Y, Saeki T, Kataoka M, Ida M, Kishino D, et al. Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys. 2000;48:751–5.CrossRef
14.
go back to reference Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7.CrossRef Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7.CrossRef
15.
go back to reference McCormick B, Ottesen RA, Hughes ME, Javid SH, Khan SA, Mortimer J, et al. Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at national comprehensive cancer network institutions. J Am Coll Surg. 2014;219:796–802.CrossRef McCormick B, Ottesen RA, Hughes ME, Javid SH, Khan SA, Mortimer J, et al. Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at national comprehensive cancer network institutions. J Am Coll Surg. 2014;219:796–802.CrossRef
16.
go back to reference Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16: 266–73. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16: 266–73.
17.
go back to reference Wickberg Å, Liljegren G, Killander F, Lindman H, Bjöhle J, Carlberg M, et al. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe. Eur J Surg Oncol. 2018;44:951–6.CrossRef Wickberg Å, Liljegren G, Killander F, Lindman H, Bjöhle J, Carlberg M, et al. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe. Eur J Surg Oncol. 2018;44:951–6.CrossRef
18.
go back to reference Fyles A, McCready D, Manchul L, et al. Preliminary results of a randomized study of tamoxifen +/- breast radiation in T1/2 N0 disease in women over 50 years of age. Proc ASCO. 2001;20:24a. Fyles A, McCready D, Manchul L, et al. Preliminary results of a randomized study of tamoxifen +/- breast radiation in T1/2 N0 disease in women over 50 years of age. Proc ASCO. 2001;20:24a.
19.
go back to reference Hughes KS, Schnaper L, Berry D, et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER +) breast carcinoma. Proc ASCO. 2001;20:24a. Hughes KS, Schnaper L, Berry D, et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER +) breast carcinoma. Proc ASCO. 2001;20:24a.
20.
go back to reference The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combinatiuon with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802–10. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combinatiuon with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802–10.
21.
go back to reference Wickberg Å, Magnuson A, Holmberg L, Adami HO, Liljegren G. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy. Breast. 2018;42:54–60.CrossRef Wickberg Å, Magnuson A, Holmberg L, Adami HO, Liljegren G. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy. Breast. 2018;42:54–60.CrossRef
22.
go back to reference Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6.CrossRef Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6.CrossRef
Metadata
Title
A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy
Authors
Shozo Ohsumi
Reiki Nishimura
Norikazu Masuda
Sadako Akashi-Tanaka
Kimito Suemasu
Hideko Yamauchi
Eriko Tokunaga
Tadashi Ikeda
Tsunehiro Nishi
Hiroto Hayashi
Yuichi Iino
Yuichi Takatsuka
Yasuo Ohashi
Hideo Inaji
Publication date
30-09-2022
Publisher
Springer Nature Singapore
Published in
Breast Cancer / Issue 1/2023
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-022-01406-5

Other articles of this Issue 1/2023

Breast Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine